Сhronic rhinosinusitis in adult patients with cystic fibrosis receiving CFTR modulators

Cystic fibrosis-associated chronic rhinosinusitis (CRS) is a separate form of CRS that progresses gradually over the course of patient’s life and worsens with age. The reasons for this are the mechanical congestion of mucus in the paranasal sinuses and the persistence of colonies of pathogenic antibiotic-resistant microorganisms. Therapy with CFTR modulators has resulted in a significant reduction in the severity of CRS. The nature of these changes and the dynamics in the microbial landscape of the upper respiratory tract are not sufficiently explored.

Aim of the article is to highlight various aspects of the impact of CFTR modulators on the course of CRS in adult patients with cystic fibrosis (CF) based on literature data and a number of our own clinical observations. The article presents a series of clinical cases of CRS in adult CF patients treated with CFTR modulators for different periods of time.

Conclusion. During targeted therapy with CFTR modulators, the symptoms of CRS are reversed due to the restoration of normal rheological properties of nasal secretions, the clinical picture improves, and the severity of CRS decreases. However, this type of treatment has no direct effect on the microbial landscape of the respiratory tract and requires additional interventions in the form of local and systemic antibacterial therapy. Therapy with CFTR modulators alters the course of CF in the nasal cavity, as well as in the pharynx and larynx.

1. Fokkens W.J., Lund V.J., Hopkins C. et al. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology. 2020; 58 (Suppl. S29): 1–464. DOI: 10.4193/rhin20.600.

2. Mainz, J.G., Naehrlich L., Schien M. et al. Concordant genotype of upper and lower airways P. aeruginosa and S. aureus isolates in cystic fibrosis. Thorax. 2009; 64 (6): 535–540. DOI: 10.1136/thx.2008.104711.

3. Hamilos D.L. Nasal and sinus problems in cystic fibrosis patients. In: Bachert C., Bourdin A., Chanez P., eds. The nose and sinuses in respiratory disorders. Sheffield: European Respiratory Society; 2017: 48–66. DOI: 10.1183/2312508X.10009616.

4. Shumkova G.L., Amelina E.L., Svistushkin V.M. et al. [Chronic rhinosinusitis in adult patients with cystic fibrosis: clinical manifestation and therapeutic approaches]. Pul’monologiya. 2019; 29 (3): 311–320. DOI: 10.18093/0869-0189-2019-29-3-311-320 (in Russian).

5. Berkhout M.C., van Rooden CJ, Rijntjes E. et al. Sinonasal manifestations of cystic fibrosis: a correlation between genotype and phenotype? J. Cyst. Fibrosis. 2014; 13 (4): 442–448. DOI: 10.1016/j.jcf.2013.10.011.

6. Mainz J.G., Koitschev A. Pathogenesis and management of nasal polyposis in cystic fibrosis. Curr. Allergy Asthma Rep. 2012; 12 (2): 163–174. DOI: 10.1007/s11882-012-0250-y.

7. Kondratenko O.V., Zhestkov A.V., Lyamin A.V., Polikarpova S.V. [Microbiota of the respiratory tract in patients with cystic fibrosis]. Byulleten’ Orenburgskogo nauchnogo tsentra UrO RAN. 2019; (3): 1–8. Available at: https://cyberleninka.ru/article/n/mikrobiota-respiratornogo-trakta-u-patsientov-s-mukovistsidozom?ysclid=lteb0xjjug10993699 (in Russian).

8. McCormick J., Cho D.Y., Lampkin B. et al. Ivacaftor improves rhinologic, psychologic, and sleep-related quality of life in G551D cystic fibrosis patients. Int. Forum Allergy Rhinol. 2019; 9 (3): 292–297. DOI: 10.1002/alr.22251.

9. Sheikh S.I., Long F.R., McCoy K.S. et al. Ivacaftor improves appearance of sinus disease on computerised tomography in cystic fibrosis patients with G551D mutation. Clin. Otolaryngol. 2015; 40 (1): 16–21. DOI: 10.1111/coa.12310.

10. Wucherpfennig L., Wuennemann F., Eichinger M. et al. Longterm effects of lumacaftor/ivacaftor on paranasal sinus abnormalities in children with cystic fibrosis detected with magnetic resonance imaging. Front. Pharmacol. 2023; 14: 1161891. DOI: 10.3389/fphar.2023.1161891.

11. Stapleton A. L., Kimple A.J., Goralski J.L. et al. Elexacaftor-TezacaftorIvacaftor improves sinonasal outcomes in cystic fibrosis. J. Cyst. Fibros. 2022; 21 (5): 792–799 DOI: 10.1016/j.jcf.2022.03.002.